InsidersTradesSigma
Track the Repligen CORP stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Repligen CORP has published 81 insider filings. Market capitalisation: €9.4bn. The latest transaction was filed on 20 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: DAWES KAREN A. All data is free.
81
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€5m
19 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Repligen CORP Strong Buy (bullish), based on 20 analysts. Average price target: US$185.70.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,871 of 29,056 companies
37.0
score / 100
Value27
Quality48
FCF yld0.9%
Earn yld0.5%
EV/EBITDA58.8x
ROE2.0%
Gross mgn52%
Net mgn6.6%
Debt/EBITDA3.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations81 total
5,426 shares@ US$180.00CommonSEC144:0001959173-26-006257
530 shares@ US$150.000.0009% mcap22.3% of flowCommon StockSEC:0001193125-26-307925:0
530 shares@ US$150.000.0009% mcap28.7% of flowCommonSEC144:0001959173-26-005250
733 sharesCommon StockSEC:0001193125-26-285449:0
733 shares@ US$145.000.0013% mcap54.3% of flowCommonSEC144:0001959173-26-004882
3,832 shares@ US$140.000.0065% mcap100.0% of flowCommon StockSEC:0001193125-26-169682:0
125 shares0Common StockSEC:0001193125-26-093379:0
125 shares0Common StockSEC:0001193125-26-093368:0
1,478 shares@ US$128.7332.0% of flowCommon StockSEC:0001193125-26-087669:0
344 shares@ US$128.732.2% of flowCommon StockSEC:0001193125-26-087595:0
9,897 shares@ US$124.9719.5% of flowCommon StockSEC:0001193125-26-087591:0
327 shares@ US$128.7345.3% of flowCommon StockSEC:0001193125-26-087579:0
444 shares@ US$128.733.2% of flowCommon StockSEC:0001193125-26-087568:0
221 shares@ US$124.97100.0% of flowCommon StockSEC:0001193125-26-087447:0
2,288 shares0Common StockSEC:0001193125-26-010470:0
275 shares@ US$161.003.3% of flowCommon StockSEC:0001193125-25-324912:0
3,366 shares@ US$26.12100.0% of flowCommon StockSEC:0001193125-25-322821:0
2,000 sharesCommon StockSEC:0001193125-25-311290:0
7,041 shares@ US$170.0063.0% of flowCommon StockSEC:0001193125-25-300642:0
2,191 shares@ US$151.2183.4% of flowCommon StockSEC:0001193125-25-288160:0
1,784 shares@ US$151.015.4% of flowCommon StockSEC:0001193125-25-283092:0
25,000 shares@ US$33.8717.8% of flowCommon StockSEC:0001193125-25-280266:0
1,248 shares@ US$145.2325.3% of flowCommon StockSEC:0001193125-25-231365:0
412 shares@ US$121.68100.0% of flowCommon StockSEC:0001193125-25-220202:0
20,000 shares@ US$33.8717.1% of flowCommon StockSEC:0001193125-25-201224:0
25 of 81 declarations
关于 Repligen CORP
Repligen Corp. (NASDAQ: RGEN) 是一家在美国纳斯达克市场上市的生命科学公司，专注于生物制药生产中使用的生物工艺技术。公司总部位于马萨诸塞州沃尔瑟姆，致力于成为生产单克隆抗体、重组蛋白、RNA 疗法、疫苗以及特定细胞和基因疗法的制药和生物技术客户的技术合作伙伴。尽管 Repligen 在生命科学领域拥有悠久的运营历史，但其目前的业务概况是由以创新、工艺效率和专有产品组合扩展为核心的增长战略所定义的。([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000095017025038999/rgen-20241231.htm?utm_source=openai)) 在运营方面，Repligen 开发并商业化了一系列广泛的系统和耗材，用于上游和下游生物制造工作流程。其产品组合包括过滤解决方案、层析产品、过程分析以及实时质量和过程控制工具。这种组合使公司处于专业化、高价值的地位，而非广泛的工业供应商。Repligen 的竞争优势来自于其对关键任务流程步骤的关注、其创新节奏以及其服务于寻求更高通量、更好重现性和更低制造风险的客户的能力。在其终端市场中，公司与成熟的生命科学工具和生物工艺供应商竞争，但通过技术深度和以客户为中心的方法实现差异化。([sec.gov](https://www.sec.gov/Archives/edgar/data/730272/000095017025038999/rgen-20241231.htm?utm_source=openai)) Repligen 还拥有多元化的国际业务布局。其公司总部位于马萨诸塞州沃尔瑟姆，大部分制造基地位于美国，并辅以爱沙尼亚、法国、德国、爱尔兰、荷兰和瑞典等地的关键设施。这种地理分布增强了供应链的弹性，并使公司能够直接进入主要的全球生物工艺中心。([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2025/Repligen-Launches-the-CTech-SoloVPE-PLUS-System/default.aspx?utm_source=openai)) 近期亮点进一步巩固了公司的战略势头。在 2026 年初，Repligen 公布了强劲的 2025 年业绩，并发布了 2026 年指引，预示着收入将进一步增长，运营利润率将扩大。在 2025 年期间，公司推出了针对生物制药制造商的 CTech SoloVPE PLUS 系统，并收购了 908 Devices 的生物工艺分析产品组合，增加了实时监测和表征工具。这些发展支持了一个明确的投资叙事：Repligen 正在稳步拓展其技术平台，并巩固其在生物制造基础设施更高价值领域的地位。([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai))
